These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 19627167

  • 1. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
    Kemp SF.
    BioDrugs; 2009; 23(3):155-63. PubMed ID: 19627167
    [Abstract] [Full Text] [Related]

  • 2. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [Abstract] [Full Text] [Related]

  • 3. Mecasermin rinfabate.
    Kemp SF.
    Drugs Today (Barc); 2007 Mar; 43(3):149-55. PubMed ID: 17380212
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of mecasermin rinfabate.
    Kemp SF, Fowlkes JL, Thrailkill KM.
    Expert Opin Biol Ther; 2006 May; 6(5):533-8. PubMed ID: 16610982
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mecasermin (recombinant human insulin-like growth factor I).
    Rosenbloom AL.
    Adv Ther; 2009 Jan; 26(1):40-54. PubMed ID: 19198769
    [Abstract] [Full Text] [Related]

  • 8. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.
    Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE, GH Insensitivity Syndrome Collaborative Group.
    J Clin Endocrinol Metab; 2007 Mar; 92(3):902-10. PubMed ID: 17192294
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Investigational agents for the treatment of growth hormone-insensitivity syndrome.
    Kemp SF, Thrailkill KM.
    Expert Opin Investig Drugs; 2006 Apr; 15(4):409-15. PubMed ID: 16548790
    [Abstract] [Full Text] [Related]

  • 12. Mecasermin.
    Keating GM.
    BioDrugs; 2008 Apr; 22(3):177-88. PubMed ID: 18481900
    [Abstract] [Full Text] [Related]

  • 13. Recombinant IGF-I: Past, present and future.
    Bright GM.
    Growth Horm IGF Res; 2016 Jun; 28():62-5. PubMed ID: 26822565
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
    Laron Z.
    Pediatr Endocrinol Rev; 2008 Mar; 5(3):766-71. PubMed ID: 18367997
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Recombinant human insulin-like growth factor-I therapy for children with growth disorders.
    Richmond EJ, Rogol AD.
    Adv Ther; 2008 Dec; 25(12):1276-87. PubMed ID: 19066756
    [Abstract] [Full Text] [Related]

  • 19. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
    Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, Rosenfeld RG.
    J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.